- Home
- KGEI vs ATOS Comparison
KGEI vs ATOS Comparison
Compare KGEI & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- ATOS
- Stock Information
- Founded
- KGEI 2008
- ATOS 2009
- Country
- KGEI United States
- ATOS United States
- Employees
- KGEI N/A
- ATOS N/A
- Industry
- KGEI
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- KGEI
- ATOS Health Care
- Exchange
- KGEI Nasdaq
- ATOS Nasdaq
- Market Cap
- KGEI 131.8M
- ATOS 113.7M
- IPO Year
- KGEI N/A
- ATOS 2012
- Fundamental
- Price
- KGEI $6.62
- ATOS $0.83
- Analyst Decision
- KGEI
- ATOS Strong Buy
- Analyst Count
- KGEI 0
- ATOS 3
- Target Price
- KGEI N/A
- ATOS $7.00
- AVG Volume (30 Days)
- KGEI 55.8K
- ATOS 886.8K
- Earning Date
- KGEI 11-12-2024
- ATOS 11-12-2024
- Dividend Yield
- KGEI N/A
- ATOS N/A
- EPS Growth
- KGEI 2.07
- ATOS N/A
- EPS
- KGEI 0.48
- ATOS N/A
- Revenue
- KGEI $54,654,000.00
- ATOS N/A
- Revenue This Year
- KGEI $15.83
- ATOS N/A
- Revenue Next Year
- KGEI $23.96
- ATOS N/A
- P/E Ratio
- KGEI $13.80
- ATOS N/A
- Revenue Growth
- KGEI 16.56
- ATOS N/A
- 52 Week Low
- KGEI $2.84
- ATOS $0.77
- 52 Week High
- KGEI $7.00
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- KGEI 72.33
- ATOS 27.85
- Support Level
- KGEI $6.00
- ATOS $0.91
- Resistance Level
- KGEI $6.28
- ATOS $0.94
- Average True Range (ATR)
- KGEI 0.39
- ATOS 0.06
- MACD
- KGEI 0.05
- ATOS -0.00
- Stochastic Oscillator
- KGEI 80.21
- ATOS 1.62
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. Its segments include the United States, Canada and Others. The company derives a majority of its revenue from the United States.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.